Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

CT-868

A Study of CT-868 in Type 1 Diabetes Mellitus

Carmot Therapeutics, Inc · Phase 2 · Completed · Enrollment 111

NCT06062069

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

X axis: threshold category. Y axis: participants reaching threshold, %.

261515
≥5%
≥10%
≥15%
≥20%
  • CT-868 Placebo
  • Arm 2: CT-868 Titrated to 1.8 mg
  • Arm 3: CT-868 Titrated to 4.1 mg
  • Arm 4: CT-868 Titrated to 6.6 mg
Show as table
Arm≥5%≥10%≥15%≥20%
CT-868 Low Dosen/rn/rn/rn/r
CT-868 Medium Dosen/rn/rn/rn/r
CT-868 High Dosen/rn/rn/rn/r
CT-868 Placebo2%n/rn/rn/r
Arm 2: CT-868 Titrated to 1.8 mg6%n/rn/rn/r
Arm 3: CT-868 Titrated to 4.1 mg15%n/rn/rn/r
Arm 4: CT-868 Titrated to 6.6 mg15%n/rn/rn/r

Not shown

  • CT-868 Low Dose: endpoint not reported
  • CT-868 Medium Dose: endpoint not reported
  • CT-868 High Dose: endpoint not reported